Skip to main content
. 2023 Feb 24;8(2):100788. doi: 10.1016/j.esmoop.2023.100788

Figure 2.

Figure 2

Timeline of BRAF inhibitor drug development from melanoma to tissue-agnostic approval.

ATC, anaplastic thyroid carcinoma; BTC, biliary tract cancer; CRC, colorectal cancer; ECD, Erdheim–Chester disease; FDA, Food and Drug Administration; HCL, hairy cell leukemia; NSCLC, non-small-cell lung cancer.